The University of Texas Southwestern Medical Center

1. Vertex Pharmaceuticals Incorporated $2,415,593 36 payments
2. Genentech, Inc. $2,290,611 180 payments
3. Sarepta Therapeutics, Inc. $2,254,734 244 payments
4. Genmab A/S $2,144,490 599 payments
5. Novo Nordisk AS $2,098,821 2,420 payments
6. Pfizer Inc. $1,918,927 46 payments
7. Biogen, Inc. $1,618,349 15 payments
8. Regeneron Pharmaceuticals, Inc. $1,344,198 191 payments
9. Roche Diagnostics Corporation $1,204,564 9 payments
10. Jazz Pharmaceuticals Inc. $696,366 74 payments

1. A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. $1,756,340 485 payments
2. An Openlabel Study to Evaluate the Safety Efficacy and Pharmacokinetics of Tafamidis in Patients With Transthyretinmediated Amyloidosis Post Orthotopic Heart Transplantation $1,607,925 4 payments
3. 4045-301 $1,341,256 20 payments
4. Nn9536-4999 $894,311 611 payments
5. An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 $759,382 1 payment
6. A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy $752,285 8 payments
7. RD007019_ACCORD-BP:Biomarker Guided Cardiovascular Risk Prediction among patients with Type 2 Diabetes in the ACCORD Trial $671,593 2 payments
8. CT-388-104 OW/OB with T2D $622,920 43 payments
9. A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies. $508,822 1 payment
10. A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis $495,561 3 payments

1. Other $1,352,652 38 payments
2. Patient care $616,848 190 payments
3. Non-patient care $91,795 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.